AzTrials
AzTrials

Shoulder PainICGNCT05179941

Subscapularis Indocyanine Green Perfusion Pilot Study

A study testing Perfusion with Indocyanine green in people with Shoulder Pain and Shoulder Arthritis, run by Dartmouth-Hitchcock Medical Center at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The Purpose of this pilot study is to evaluate the feasibility of open wide-field imaging of indocyanine green ingress and egress during total shoulder arthroplasty. This study also hopes to characterize the relationship between tissue perfusion measured with DCE-FI and different approaches and techniques used in… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Perfusion with Indocyanine green
Could I receive a placebo?
No, everyone receives an active treatment
How many people
10 participants
Where
1 siteUnited States
Study dates
11 Feb 2022to 13 Dec 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • - Participant must be 18 years of age or older
  • - Meet clinical and radiographic parameters necessary to undergo shoulder arthroplasty
  • - Subscapularis tendon intact clinically on exam or via advanced imaging
  • - Subject has the ability to have their shoulder arthroplasty completed using either the tenotomy or peel technique.

Who cannot join

  • - Inability of patient to provide informed consent
  • - Iodine allergy
  • - Subscapularis tendon tear or concern for tear
  • - Incarceration
  • - Pregnant women
  • - Patients less than 18 years of age
  • - Prior deltopectoral approach to the ipsilateral shoulder

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire, 03756

Other trials in United States

About this study

Official title: Pilot Feasibility Study of Dynamic Contrast-enhanced Fluorescence Imaging to Guide Total Shoulder Arthroplasty Approach

The Purpose of this pilot study is to evaluate the feasibility of open wide-field imaging of indocyanine green ingress and egress during total shoulder arthroplasty. This study also hopes to characterize the relationship between tissue perfusion measured with DCE-FI and different approaches and techniques used in total shoulder arthroplasty. The long term goal of this study is to determine if there is a potential relationship between perfusion and patient reported outcomes and subscapularis failure.

Read the detailed description

Shoulder arthroplasty is a commonly utilized and routinely successful surgery performed for management of glenohumeral joint arthritis. Upwards of 90% of primary anatomic total shoulder arthroplasty surgeries are considered successful. Albeit rare, complications do occur. Complications include glenoid or humeral component loosening, periprosthetic fracture, infection and rotator cuff failure. Of the four muscles that comprise the rotator cuff, the subscapularis is of particular concern in total shoulder arthroplasty surgery due to the approach used to access the glenohumeral joint. The deltopectoral approach is the standard approach used for shoulder arthroplasty and necessitates performing a subscapularis takedown in order to obtain adequate visualization of the glenohumeral joint. Three techniques to perform a subscapularis takedown are common, with an absence of consensus in the literature as to which technique is superior. The techniques include a subscapularis peel, and a subscapularis tenotomy.

Each subscapularis takedown technique requires repair at the conclusion of the procedure when performing shoulder arthroplasty. Repair is crucial for proper force coupling of the shoulder to keep the humeral head implant centered on the glenoid component. Takedown is still performed in a reverse total shoulder arthroplasty but repair is not required to maintain stability. Each takedown technique is reliant on a tendon to tendon interface for healing. Failure of the subscapularis tendon repair can result in pain, instability, decreased functional outcomes and ultimately the need for revision surgery. Subscapularis tendon failure can sometimes be asymptomatic, however it can also be symptomatic and present with the aforementioned signs. Subscapularis failure rates may approach 50% in long term studies although symptomatic cases likely occur in less than 1% of total shoulder arthroplasties . Due to the devastating impact on patients with symptomatic subscapularis failure, there is interest in investigating which subscapularis takedown technique produces the best outcomes. Prior randomized controlled trials as well as systematic reviews have previously been conducted looking at these different takedown techniques, but demonstrated no statistically significant difference in primary endpoints of subscapularis strength at various time endpoint and no statistically significant difference in patient reported outcomes. These prior studies did not evaluate subscapularis perfusion post repair, adequate perfusion is necessary for healing to occur with any subscapularis takedown technique.

The takedown method of the subscapularis has previously been shown to have no statistically significant differences with regards to strength, or patient reported outcomes, however if there was a difference noted in tendon perfusion post repair this may provide rationale to choose one technique over another as improved perfusion may correlate to lower risk of repair failure.

The data acquired using the SPY Elite or SPY PHI or EleVision will be deanonymized and exported to a secure PC for additional analysis and processing. The analysis techniques will be more sophisticated than the current commercial system, and involve a correction for the patient-specific arterial input function (AIF) -the cardiac and circulatory variations that can modify the time and manner in which the ICG dye arrives in the imaging field-of-view.

Indocyanine green (ICG) is a well-studied water soluble, light absorbing tracer that has been used in other capacities to help quantify tissue perfusion during surgery. ICG is able to be injected into a patient intravenously and subsequently circulate systemically while bound to albumin, quickly undergoing hepatic metabolism in just several minutes. The concentration of ICG in specific tissue is able to be quantified as a surrogate for tissue perfusion. ICG due to its IV administration and quick metabolism is able to help quantify perfusion in real time, such as intra-operatively. Systemic reviews as well as case studies, most commonly in plastic surgery, have been performed showing its utility to determine adequate or inadequate perfusion in downstream tissue in situations where microanastomoses are performed, such as with flaps and in hand surgery. Other studies have also been conducted showing the ability to use ICG as a surrogate for tissue perfusion in the achilles paratenon in humans and in rabbits who had undergone rotator cuff repair to determine tissue perfusion after different types of repair. The use of ICG imaging in orthopaedic surgery is relatively nascent, and our institution as well as other collaborators have demonstrated its promise in these applications.

Being tested
Perfusion with Indocyanine green
Keywords
Orthopaedic, Shoulder, Joint Replacement, ICG, Indocyanine green
Medical subject headings
Shoulder Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Perfusion with Indocyanine greenProcedure or surgery

    Infusion of Indocyanine green to determine perfusion of the subscapularis tendon change after tenotomy vs peel technique and subsequent intra-operative repair.

Study groups in NCT05179941
Study groupRoleWhat they receive
patients requiring a shoulder arthroplastyExperimentalPatients will be administered Food and Drug Administration (FDA) approved Indocyanine green (ICG) through intravenous injection and imaged by a FDA approved surgical fluorescence imaging device. Both ICG fluorescence and the imaging system have been used for routine clinical practice for many years. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to meniscal perfusion can be captured by an FDA approved imaging system.
Receives: Procedure: Perfusion with Indocyanine green

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. measurement of change to tendon blood supply during total shoulder arthroplasty

    The primary study outcome is to evaluate the ingress and egress in tendon and tissue blood flow in patients undergoing a total shoulder repair.

    Measured: Baseline, up to 2 hours

Secondary outcomes (1)
  1. measurement of change to tendon blood supply using different techniques used in total shoulder arthroplasty

    To characterize the relationship between tissue perfusion with different approaches used in total shoulder arthroplasty

    Measured: Baseline, up to 2 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Jan 2022
  2. Study start11 Feb 2022
  3. Primary completion13 Dec 2022
  4. Study completion13 Dec 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
10 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05179941
Sponsor's protocol ID
STUDY02001327
Acronym
ICG
Status last verified
Aug 2023
First submitted
17 Dec 2021
Last updated
4 Aug 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Perfusion with Indocyanine green in people with Shoulder Pain and Shoulder Arthritis, run by Dartmouth-Hitchcock Medical Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

measurement of change to tendon blood supply during total shoulder arthroplasty (time frame: Baseline, up to 2 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Aug 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in